Boniva print ad hyped efficacy, says DDMAC

Share this article:
Boniva print ad hyped efficacy, says DDMAC
Boniva print ad hyped efficacy, says DDMAC
A print ad for Genentech's Boniva overstated the osteoporosis drug's efficacy, said the FDA's Division of Drug Marketing, Advertising and Communication in an untitled letter.

The agency took issue with the claim in the ad, which features Sally Field, that: “Studies show, after a year on Boniva, 9 out of 10 women stopped and reversed their bone loss.”

The claim, said DDMAC, “is not supported by substantial evidence or substantial clinical experience” but rather “a per-protocol post-hoc responder analysis that the clinical study was not adequately designed to evaluate.”

Genentech, said FDA, is pulling violative promotional materials for the drug featuring that claim.

The ad that prompted the letter ran in Parade Magazine. It features an image of Field sitting on a pier, with the headline: “I wanted to stop my bone loss. But I did more. I reversed it with Boniva.”

Field has served as the face of the brand since 2006, when Roche and GlaxoSmithKline launched their “Rally with Sally for Bone Health” campaign.”
Share this article:

Email Newsletters

More in News

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.